Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch.
Stem Cell Rev Rep
; 15(3): 443-447, 2019 06.
Article
em En
| MEDLINE
| ID: mdl-30826931
ABSTRACT
T cell malignancies are aggressive diseases with no standard treatment available, often resulting in poor patient outcomes. Lately, the recent FDA approval of a CD19 CAR T cell therapy for B cell acute lymphoblastic leukemia has earned nationwide attention, leading to the possibility that success of CD19 CAR therapy can be extended to T cell malignancies. However, the impact of T cell depletion due to a shared antigen pool remains an issue to be resolved. Here, we describe a CD4CAR capable of eliminating CD4-positive T cell acute lymphoblastic leukemia in a systemic mouse model, with CAMPATH (alemtuzumab) as a natural safety switch to deplete the infused CD4CAR T cells to prevent toxicities associated with CD4 cell aplasia. Our data support the potential use of CD4CAR T cells for the treatment of CD4-postive T-cell acute lymphoblastic leukemia malignancies or refractory disease in clinical settings.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia-Linfoma Linfoblástico de Células Precursoras B
/
Linfócitos T CD4-Positivos
/
Imunoterapia Adotiva
/
Alemtuzumab
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Stem Cell Rev Rep
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos